SRNE News and Press, Sorrento Therapeutics Inc. From 01/07/22

SAN DIEGO, Jan. 07, 2022 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (NASDAQ: SRNE, "Sorrento"), announced today that Dr. Henry Ji, Chairman and CEO, will participate in the following upcoming conference: HC Wainwright BIOCONNECT Virtual Conference Presentation will be ava...

SAN DIEGO, Jan. 04, 2022 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (NASDAQ: SRNE, "Sorrento"), announced today that Dr. Henry Ji, Chairman and CEO, will participate in the following upcoming panel at the Longwood Healthcare Leaders Winter Conference: January 6 th at 11:50 am...

The last week of the year is turning out to be a rough one for many COVID-19 related stocks. Shares of Co-Diagnostics (NASDAQ: CODX) were sinking 12.4% for the week as of the market close on Thursday. Ocugen (NASDAQ: OCGN) was down 5.5% after plunging as much as 19.2% earlie...

InvestorPlace - Stock Market News, Stock Advice & Trading Tips NRx Pharmaceuticals (NASDAQ: NRXP ) stock is advancing in early trading today after the company announced that it was seeking breakthrough therapy designation from the U.S. Food and Drug Administration for its Covid-1...

Sorrento Therapeutics (NASDAQ:SRNE) announces that initial testing of COVISTIX on recombinant N proteins demonstrated its ability to detect the Omicron variant, in addition to detecting the original SARS-CoV-2 virus and other major variants of concern (VoCs) such as the delta and delta-p...

COVISTIX maintains its ability to detect the Omicron Variant, in addition to detecting SARS-CoV-2 and all of its major variants of concern (VoCs); COVISTIX has the potential to be a “Best-in-Class” rapid COVID-19 virus antigen detection test: Comparative studies with...

Sorrento Therapeutics' (NASDAQ:SRNE) subsidiary, Sorrento Therapeutics Mexico executed a second contract with a large distributor for the sale and distribution of up to 10M COVISTIX tests for the Mexican market. Earlier, Sorrento Mexico had signed a contract with a leading local dis...

Sorrento Therapeutics' (NASDAQ:SRNE) Mexican subsidiary has executed a second contract with a large distributor for the sale and distribution of up to 10 million COVISTIX tests for the Mexican market. SRNE previously announced that Sorrento Mexico had signed a contract with a local distributo...

SAN DIEGO and MEXICO CITY, Dec. 27, 2021 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (Nasdaq: SRNE, “Sorrento”) announced today its subsidiary, Sorrento Therapeutics Mexico (“Sorrento Mexico”), has executed a second contract with a large distributor for the s...

The FDA has authorized Sorrento Therapeutics' (NASDAQ:SRNE) IND application for a phase 1b trial of STI-1386 (Seprehvec) for oncolytic virus in patients with relapsed or refractor solid tumors. "Seprehvec allows for locoregional immune stimulation at the tumor site while potentially mini...